ABIVAX: 2016 Financial Calendar

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

December 10, 2015 12:00 PM UTC

PARIS--(BUSINESS WIRE)--

Regulatory News:

ABIVAX (Paris: ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced its financial reporting schedule for 2016.

Financial publications will be issued after the market close. This schedule is indicative and subject to change.

  • Half-year report on the liquidity contract: January 7, 2016
  • 2016 Full-year Results: March 15, 2016
  • Publication of the 2016 Financial Annual Report: April 28, 2016
  • Annual General Meeting: June 24, 2016
  • Half-year report on the liquidity contract: July 7, 2016
  • 2016 Half-year Results: September 20, 2016
  • Publication of the 2016 Financial Half-Year Report: September 28, 2016

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

Follow us on Twitter @ABIVAX_

ABIVAX
Investor relations Press relations
Raquel Lizarraga, +33 1 53 83 09 63
[email protected]
or
ALIZE RP
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / + 33 1 44 54 36 64
[email protected]
or
Citigate Dewe Rogerson
Lucie Larguier, +33 1 53 32 84 75
[email protected]
or
Life Sci Advisors
Chris Maggos, +41 79 367 6254
[email protected]

Source: ABIVAX


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

Twitter